US EditionDenmark Compensates Four over Vision Loss Linked to Ozempic, Wegovy
Denmark's independent body ruled four patients eligible for compensation after vision loss linked to semaglutide drugs, which affect 1 in 10,000 users, the Pharmacovigilance Risk Assessment Committee said.
- On Friday at The Hindu's Lit for Life Dialogue 2025, panelists at the Museum of Art and Photography, Bengaluru said Ozempic should be taken under doctor’s advice and used to support weight loss, not as a quick fix.
- Experts noted that the drug alters appetite hormones, so Ozempic curbs cravings by changing hormones controlling appetite and satiety, fitting obesity's medical definition due to related health issues.
- The endocrinologist said the minimum weaning should be at least two years, warning unregulated short-term use could have long-term repercussions and recommending dosage tapering with diet and exercise.
- On November 21, 2025, a Danish panel ruled that four people who developed NAION after using Wegovy and Ozempic merit 800,000 kroner compensation, the Danish Patient Compensation association said.
- Following PRAC's findings, Novo Nordisk updated patient leaflets to include NAION as a "very rare" side effect affecting up to 1 in 10,000 users, after a 2024 review request by the Danish Medicines Agency.
40 Articles
40 Articles
Dr. Terry Dubrow Tries to Explain the Reality of ‘Ozempic Penis’
Botched star Dr. Terry Dubrow is ready to showcase his latest knowledge about the weight-loss drug, Ozempic, and its effects on the penis. “There’s a new Ozempic-related disorder,” Terry, 67, shared on the Monday, November 24 episode of iHeartRadio’s “Between Us” podcast. “Ozempic penis. It is a thing.” While his wife and cohost, Heather Dubrow, had no idea what it was, she tried to guess that it must be related to having “trouble getting hard.”…
New Moms' GLP-1 Prescriptions Jumped After Wegovy Approval
(MedPage Today) -- Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for weight loss, a Danish epidemiological study found. In the first quarter of 2018, there were less...
Denmark compensates patients for vision loss linked to Novo Nordisk drugs
Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient Compensation association said on Friday.
Denmark compensates four over vision loss linked to Ozempic
Read: 2 min Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday. More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association. The condition —…
Medicines such as Wegovy and Ozempic are very popular in the fight against obesity. However, they have a rare but severe side effect: a marked visual deterioration. In Denmark, dozens of people suffer from the disease demand compensation. Four of them receive compensation - further applications are still ongoing.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
